Table 1.
Laboratory investigations during the first half of hospital admission
| Variable | Reference range | Day 1 | Day 3 | Day 6 | Day 9* | Day 12 |
|---|---|---|---|---|---|---|
| Haematology | ||||||
| Haemoglobin (g/L) | 135–172 | 102 | 99 | 101 | 85 | 78 |
| White cells (× 109/L) | 3.9–10.2 | 4.7 | 6.4 | 6.9 | 8.3 | 9.7 |
| Differential count (× 109/L) | ||||||
| Lymphocytes | 1.1–4.5 | 0.49 | 0.45 | 0.77 | 1.78 | 3.30 |
| Basophils | 0–0.2 | 0.02 | 0.00 | 0.00 | 0.13 | 0.00 |
| Eosinophils | 0.02–0.5 | 0.24 | 0.32 | 0.74 | 0.27 | 0.19 |
| Monocytes | 0.1–0.9 | 0.42 | 0.96 | 0.49 | 0.56 | 0.29 |
| Neutrophils | 1.5–7.7 | 3.23 | 4.67 | 3.98 | 4.73 | 5.72 |
| Platelets (× 109/L) | 150–370 | 141 | 115 | 144 | 116 | 151 |
| Prothrombin time international normalised ratio | 1–1.15 | 1.45 | – | 1.83 | 1.39 | 1.20 |
| Fibrinogen (g/L) | 1.46–3.33 | – | 2.71 | 2.45 | 2.12 | 1.11 |
| Biochemistry | ||||||
| Sodium (mmol/L) | 133–146 | 130 | 129 | 126 | 136 | 137 |
| Potassium (mmol/L) | 3.5–5.3 | 4.2 | 4.8 | 5.5 | 4.9 | 4.7 |
| Urea (mmol/L) | 2.5–7.8 | 12.4 | 15.5 | 28.7 | 11.8 | 31.0 |
| Creatinine (μmol/L) | 62–115 | 202 | 311 | 594 | 137 | 250 |
| Alanine transaminase (U/L) | 10–49 | 43 | 60 | 105 | 122 | 94 |
| Alkaline phosphatase (U/L) | 30–130 | 127 | 223 | 428 | 910 | 717 |
| Albumin (g/L) | 35–50 | 32 | 27 | 22 | 17 | 23 |
| Total bilirubin (μmol/L) | 0–20 | 12 | 34 | 117 | 98 | 46 |
| Tacrolimus (μg/L) | 5–8 | > 30 | 25.5 | 11.3 | 5.1 | 3.6 |
| C-reactive protein (mg/L) | 0–6 | 256 | 276 | 309 | 235 | 53 |
| Procalcitonin (ng/mL) | 0–0.5 | 6.13 | – | – | 13.25 | 12.59 |
| Ferritin (μg/L) | 22–322 | – | 3164.7 | 8937.9 | 8829.9 | 2640.0 |
| Triglyceride (mmol/L) | 0.3–1.8 | – | 1.61 | 1.74 | 1.82 | 3.82 |
| Interleukin-1 beta (pg/mL) | 0–3.1 | – | – | 2.04 | 0.10 | – |
| Interleukin-6 (pg/mL) | 0–2 | – | – | 434.31 | 8.82 | – |
| Interleukin-10 (pg/mL) | 0–1 | – | – | 20.99 | 14.59 | – |
| Tumour necrosis factor alpha (pg/mL) | 0–5 | – | – | 250.19 | 66.82 | – |
| Interferon gamma (pg/mL) | 0–10 | – | – | 52.84 | 7.81 | – |
| Virology | ||||||
| Nasopharyngeal SARS-CoV-2 (cycle threshold) | N/A | 27 | – | – | – | 15 |
| EBV PCR | N/A | 1.3 × 107 | – | – | – | – |
| Urine analysis | ||||||
| Blood | N/A | Neg | Trace | – | – | Trace |
| Leukocytes | N/A | Neg | Neg | – | – | Neg |
| Protein | N/A | – | 3 + | – | – | Neg |
*48 h post RTX administration and commencement of dexamethasone